Heuck C C, Ritz E
Nephron. 1980;25(1):1-7. doi: 10.1159/000181745.
In uremic patients, hyperlipoproteinemia is common, but its role as a risk factor in atherogenesis remains controversial. The main abnormality appears to be diminished catabolism of lipoproteins in the face of unchanged or low hepatic synthesis. The relation of diminished catabolism to reduced postheparinlipolytic activity and selective deficiency of hepatic triglyceride lipase remains to be established. Hyperlipoproteinemia in uremic patients, most commonly of the type IV variety, responds to dietary methods (reduction of carbohydrate content, increase in P/S ratio) or pharmacological intervention. Guidelines for therapy remain controversial in view of the uncertainty about the pathogenic role of hyperlipoproteinemia in atherogenesis.
在尿毒症患者中，高脂蛋白血症很常见，但其作为动脉粥样硬化危险因素的作用仍存在争议。主要异常似乎是在肝脏合成不变或降低的情况下，脂蛋白分解代谢减少。分解代谢减少与肝素后脂解活性降低和肝脏甘油三酯脂肪酶选择性缺乏之间的关系仍有待确定。尿毒症患者的高脂蛋白血症，最常见的是IV型，对饮食方法（减少碳水化合物含量，增加P/S比值）或药物干预有反应。鉴于高脂蛋白血症在动脉粥样硬化发病机制中的致病作用尚不确定，治疗指南仍存在争议。
